Table III.
Treatment persistence of systemic and topical treatments for atopic dermatitis stratified by region
| Treatment | Treatment persistence |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholm |
South |
West |
Other |
|||||||||
| Patients, n | Median (months) | 95% CI | Patients, n | Median (months) | 95% CI | Patients, n | Median (months) | 95% CI | Patients, n | Median (months) | 95% CI | |
| Systemic treatments | ||||||||||||
| Alitretinoin | 87 | 5.4 | 4.4–6.8 | 43 | 4.4 | 3.8–6.1 | 27 | 6.1 | 3.7–7.4 | 60 | 4.4 | 3.9–5.7 |
| Azathioprine | 201 | 9.9 | 7.2–15.4 | 162 | 12.0 | 6.9–16.2 | 105 | 15.7 | 7.3–22.7 | 314 | 10.4 | 6.1–13.8 |
| Cyclosporine | 217 | 3.2 | 2.6–3.5 | 141 | 4.0 | 3.4–5.4 | 187 | 3.2 | 2.6–3.6 | 413 | 3.7 | 3.2–4.3 |
| Dupilumab | 180 | NRa | – | 135 | NRa | – | 105 | NRa | – | 187 | NRa | – |
| Methotrexate | 760 | 11.2 | 10.2–12.9 | 523 | 13.2 | 12.0–15.9 | 375 | 14.0 | 11.5–17.0 | 944 | 12.9 | 11.4–14.5 |
| Mycophenolate | 32 | 6.4 | 3.7–10.4 | 32 | 5.8 | 2.5–9.2 | 57 | 4.9 | 2.6–7.8 | 61 | 5.1 | 2.5–8.1 |
| Topical treatments | ||||||||||||
| Dispensed emollients | 1,117 | 18.4 | 17.4–20.1 | 744 | 17.3 | 15.3–18.0 | 602 | 17.9 | 16.4–20.3 | 1,420 | 20.3 | 17.9–22.1 |
| Pimecrolimus | 242 | 6.1 | 5.9–8.1 | 153 | 7.6 | 5.9–10.5 | 112 | 7.5 | 5.9–10.2 | 203 | 6.6 | 5.9–8.3 |
| Tacrolimus | 720 | 8.4 | 7.2–9.6 | 444 | 7.2 | 5.9–8.5 | 405 | 6.4 | 5.9–7.6 | 811 | 8.3 | 7.4–9.9 |
| Topical corticosteroids | 1,132 | 16.7 | 15.5–17.8 | 771 | 18.3 | 16.6–21.0 | 631 | 17.8 | 15.7–20.9 | 1,460 | 19.4 | 17.7–21.8 |
Duration of treatment persistence was defined as the time from the first dispensation of treatment to discontinuation. Patients were considered persistent with a treatment if the gap between dispensations (i.e. from the end of supply plus days supplied of the former dispensation to the dispensation date of the next) was less than the “grace period” (Appendix S1). A discontinuation was recorded if the patient switched to another drug or had no treatment dispensed after the grace period. For some patients, information on region was not recorded in the register and so the total number of patients for stratification by region was lower for all treatments, except dupilumab, than the overall number of patients included in cohort 2 for each treatment. Further detail for the 4 regions of “Stockholm”, “south”, “west” and “other” is provided as Appendix SI; STable I.
Follow-up time too short to estimate the median treatment persistence for dupilumab.
CI: confidence interval; NR: not reached.